Cell, gene and RNA therapies have been widely adopted by the major pharma players. While their growth is tremendous (52% CAGR up to 2026), they will only account for up to 7% of total market size by 2026.
The US Food and Drug Administration's (FDA) website currently references 23 approved cell and gene therapies, including six CAR-T products, the most recent of which was Johnson & Johnson Carvykti for multiple myeloma. (Also see "Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti" - Scrip, 1 March, 2022
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?